Peter McCroskery

1.1k total citations
18 papers, 904 citations indexed

About

Peter McCroskery is a scholar working on Rheumatology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Peter McCroskery has authored 18 papers receiving a total of 904 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 6 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Peter McCroskery's work include Multiple Sclerosis Research Studies (4 papers), Protease and Inhibitor Mechanisms (3 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Peter McCroskery is often cited by papers focused on Multiple Sclerosis Research Studies (4 papers), Protease and Inhibitor Mechanisms (3 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Peter McCroskery collaborates with scholars based in United States, United Kingdom and Germany. Peter McCroskery's co-authors include Edward D. Harris, J.F. Richards, Stephen M. Krane, Edward P. Amento, Edward J. Miller, John Edward Finch, William T. Butler, Elvin Harper, John H. Highberger and Clare Corbett and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Peter McCroskery

18 papers receiving 819 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter McCroskery United States 12 248 246 179 149 117 18 904
Masayuki Shinmei Japan 22 1.1k 4.5× 326 1.3× 226 1.3× 211 1.4× 93 0.8× 42 1.7k
A. A. Cole United States 17 717 2.9× 194 0.8× 268 1.5× 148 1.0× 99 0.8× 27 1.3k
Gavin C. Jones United Kingdom 13 136 0.5× 139 0.6× 186 1.0× 82 0.6× 40 0.3× 17 876
Klaus Huch Germany 16 802 3.2× 246 1.0× 195 1.1× 105 0.7× 52 0.4× 27 1.4k
Lynda O’Rear United States 15 365 1.5× 148 0.6× 593 3.3× 231 1.6× 45 0.4× 22 1.4k
B C Adelmann-Grill Germany 19 60 0.2× 145 0.6× 158 0.9× 59 0.4× 69 0.6× 32 1.1k
Marina D’Angelo United States 16 320 1.3× 158 0.6× 492 2.7× 135 0.9× 76 0.6× 20 1.1k
Anthony Sellers United States 13 255 1.0× 362 1.5× 339 1.9× 187 1.3× 124 1.1× 15 1.0k
Robert Dinser Germany 16 779 3.1× 234 1.0× 474 2.6× 287 1.9× 120 1.0× 32 1.7k
Rachel A. Oldershaw United Kingdom 13 425 1.7× 123 0.5× 505 2.8× 68 0.5× 122 1.0× 30 1.2k

Countries citing papers authored by Peter McCroskery

Since Specialization
Citations

This map shows the geographic impact of Peter McCroskery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter McCroskery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter McCroskery more than expected).

Fields of papers citing papers by Peter McCroskery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter McCroskery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter McCroskery. The network helps show where Peter McCroskery may publish in the future.

Co-authorship network of co-authors of Peter McCroskery

This figure shows the co-authorship network connecting the top 25 collaborators of Peter McCroskery. A scholar is included among the top collaborators of Peter McCroskery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter McCroskery. Peter McCroskery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Strati, Paolo, Lori A. Leslie, Parveen Shiraz, et al.. (2022). Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.. Journal of Clinical Oncology. 40(16_suppl). 7567–7567. 5 indexed citations
2.
McCroskery, Peter, Krzysztof Selmaj, Óscar Fernández, et al.. (2017). Safety and Tolerability of Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial (P5.369). Neurology. 88(16_supplement). 10 indexed citations
3.
Giovannoni, Gavin, Heinz Wiendl, Benjamin Turner, et al.. (2017). Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta. Multiple Sclerosis Journal. 24(13). 1725–1736. 3 indexed citations
4.
Mehta, Devangi, Katherine Riester, James P. Sheridan, et al.. (2016). Reversible Effects of Daclizumab HYP on Lymphocyte Counts in RRMS Patients: Data from the SELECT Trilogy Studies (P5.281). Neurology. 86(16_supplement). 2 indexed citations
5.
6.
Giovannoni, Gavin, Ludwig Kappos, Ralf Gold, et al.. (2016). Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Multiple Sclerosis and Related Disorders. 9. 36–46. 44 indexed citations
7.
Gold, Ralf, Dusan Stefoski, Krzysztof Selmaj, et al.. (2016). Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurology and Therapy. 5(2). 169–182. 13 indexed citations
8.
Borad, Mitesh J., Henry C. Pitot, Joseph Rubin, et al.. (2012). Pilot Study of Tigatuzumab (CS-1008) in Combination with Folfiri in Patients with Metastatic Colorectal Cancer (CRC). Annals of Oncology. 23. ix222–ix222. 1 indexed citations
9.
McCroskery, Peter, Carol A. Wallace, Daniel J. Lovell, et al.. (2010). Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatric Rheumatology. 8(1). 18–18. 31 indexed citations
10.
Gibofsky, Allan, William Palmer, Edward Keystone, et al.. (2010). Rheumatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the RADIUS 1 and RADIUS 2 Registries. The Journal of Rheumatology. 38(1). 21–28. 22 indexed citations
11.
Kimball, Alexa B., David M. Pariser, Paul S. Yamauchi, et al.. (2010). OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. 16a(3). 3–7. 4 indexed citations
12.
McCroskery, Peter, et al.. (1985). Stimulation of procollagenase synthesis in human rheumatoid synovial fibroblasts by mononuclear cell factor/interleukin 1. FEBS Letters. 191(1). 7–12. 40 indexed citations
13.
Stephenson, Mary L., Stephen M. Krane, Edward P. Amento, Peter McCroskery, & M. Byrne. (1985). Immune interferon inhibits collagen synthesis by rheumatoid synovial cells associated wth decreaded levels of the procollagen mRNAs(FEBS 2156). FEBS Letters. 180(1). 43–50. 79 indexed citations
14.
15.
McCroskery, Peter, J.F. Richards, & Edward D. Harris. (1975). Purification and characterization of a collagenase extracted from rabbit tumours. Biochemical Journal. 152(1). 131–142. 148 indexed citations
16.
Harris, Edward D. & Peter McCroskery. (1974). The Influence of Temperature and Fibril Stability on Degradation of Cartilage Collagen by Rheumatoid Synovial Collagenase. New England Journal of Medicine. 290(1). 1–6. 146 indexed citations
17.
Gross, Jerome, Elvin Harper, Edward D. Harris, et al.. (1974). Animal collagenases: Specificity of action, and structures of the substrate cleavage site. Biochemical and Biophysical Research Communications. 61(2). 605–612. 128 indexed citations
18.
McCroskery, Peter, et al.. (1973). Gelatin: A Poor Substrate for a Mammalian Collagenase. Science. 182(4107). 70–71. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masayuki Shinmei Breakdown of academic impact, for papers by A. A. Cole Breakdown of academic impact, for papers by Gavin C. Jones Breakdown of academic impact, for papers by Klaus Huch Breakdown of academic impact, for papers by Lynda O’Rear Breakdown of academic impact, for papers by B C Adelmann-Grill Breakdown of academic impact, for papers by Marina D’Angelo Breakdown of academic impact, for papers by Anthony Sellers Breakdown of academic impact, for papers by Robert Dinser Breakdown of academic impact, for papers by Rachel A. Oldershaw
Rankless by CCL
2026